Publications by authors named "J Andel"

Global satellite navigation systems (GNSSs) are the most-used technology for the localization of vehicles in the outdoor environment, but in the case of a densely built-up area or during passage through a tunnel, the satellite signal is not available or has poor quality. Inertial navigation systems (INSs) allow localization dead reckoning, but they have an integration error that grows over time. Inexpensive inertial measurement units (IMUs) are subject to thermal-dependent error and must be calibrated almost continuously.

View Article and Find Full Text PDF

Understanding the impact of induction and maintenance therapy on patients' quality of life (QoL) is important for treatment selection. This study aims to compare patient-reported QoL between patients treated with KTd or KRd induction therapy and K maintenance therapy or observation. QoL was assessed using the EORTC QOL-C 30 and QOL-MY20 questionnaires in the AGMT-02 study, in which 123 patients with newly diagnosed transplant ineligible multiple myeloma were randomized to nine cycles of either KTd or KRd induction therapy, followed by 12 cycles of K maintenance therapy, or observation.

View Article and Find Full Text PDF

Randomized comparison between KTd and KRd induction followed by second randomization to carfilzomib in transplant-ineligable patients with newly diagnosed multiple myeloma.

View Article and Find Full Text PDF

At the beginning of 2020, the large and unforeseen inflow of COVID-19 patients had a deep impact on the healthcare operations of Dutch hospitals. From a patient flow logistics perspective, each hospital handled the situation largely in its own particular and improvised way. Nevertheless, some hospitals appeared to be more effective in their dealing with this sudden demand for extra care than others.

View Article and Find Full Text PDF

Background: Twenty percent of colorectal cancer liver metastases (CLMs) are initially resectable with a 5-year survival rate of 25%-40%. Perioperative folinic acid, 5-fluorouracil, oxaliplatin (FOLFOX) increases progression-free survival (PFS). In advanced disease, the addition of targeting therapies results in an overall survival (OS) advantage.

View Article and Find Full Text PDF